KZIA - Kazia Therapeutics Limited
NASDAQ
->
Healthcare
->
Biotechnology
Sydney,
Australia
Type: Equity
KZIA price evolution
KZIA
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.66 | $3.56 | $5.24 | $4.39 |
| Short term investments | ||||
| Net receivables | $3.9 | $3.74 | $3.9 | $0.74 |
| Inventory | ||||
| Total current assets | $6.14 | $8.01 | $10.77 | $5.92 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $21.59 | $24.38 | $28.09 | $27.84 |
| Current liabilities | ||||
| Accounts payable | $4.55 | $1.04 | $0.86 | $2.31 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $25.8 | $11.34 | $7.57 | $5.58 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $31.6 | $19.12 | $16.03 | $16.25 |
| Shareholders' equity | ||||
| Retained earnings | -$110.91 | -$93.05 | -$84.66 | -$77.99 |
| Other shareholder equity | -$0.75 | -$0.85 | -$0.74 | -$0.77 |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.66 | $5.24 | $7.36 | $27.59 |
| Short term investments | ||||
| Net receivables | $3.9 | $3.9 | $0.09 | $0.08 |
| Inventory | ||||
| Total current assets | $6.14 | $10.77 | $7.61 | $29.39 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $21.44 | |||
| Total investments | ||||
| Total assets | $21.59 | $28.09 | $34.96 | $58.09 |
| Current liabilities | ||||
| Accounts payable | $4.55 | $0.86 | $1.52 | $1.89 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $25.8 | $7.57 | $4.69 | $8.33 |
| Long term debt | ||||
| Total noncurrent liabilities | $8.9 | |||
| Total debt | ||||
| Total liabilities | $31.6 | $16.03 | $16.32 | $20.24 |
| Shareholders' equity | ||||
| Retained earnings | -$110.91 | -$84.66 | -$64.99 | -$44.2 |
| Other shareholder equity | -$0.75 | -$0.74 | -$0.85 | $1.76 |
| Total shareholder equity | $18.64 | $37.85 | ||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.31 | $0.01 | $0.02 | $0 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $20.89 | $8.8 | $10.51 | $13.64 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.14 | -$0.14 | -$0.14 | -$0.14 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$17.95 | -$8.82 | -$6.88 | -$13.59 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.32 | $0.02 | $0 | $15.18 |
| Cost of revenue | ||||
| Gross Profit | $15.18 | |||
| Operating activities | ||||
| Research & development | $14.54 | |||
| Selling, general & administrative | $7.02 | |||
| Total operating expenses | $29.51 | $24.15 | $24.88 | $21.56 |
| Operating income | -$6.38 | |||
| Income from continuing operations | ||||
| EBIT | -$6.38 | |||
| Income tax expense | -$0.27 | -$0.27 | -$0.37 | -$0.48 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$26.78 | -$20.47 | -$24.65 | -$8.42 |
| Income (for common shares) | -$8.42 | |||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.99 | $4.75 | $12.97 | $5.85 |
| Effect of exchange rate | $0.01 | -$0.1 | $0.06 | -$0.02 |
| Change in cash and equivalents | -$3.58 | -$1.68 | -$2.12 | -$2.97 |
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jun 2021 |
|---|---|---|---|---|
| Net income | -$8.42 | |||
| Operating activities | ||||
| Depreciation | $1.27 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$9.11 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$2.36 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.99 | $12.97 | $3.73 | $28.11 |
| Effect of exchange rate | $0.01 | $0.06 | $1.18 | -$0.18 |
| Change in cash and equivalents | -$3.58 | -$2.12 | -$20.23 | $18.82 |
News
Fundamentals
| Market cap | $3.91M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 504.07K |
| Revenue | $2.34M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$47.24M |
| Revenue Q/Q | 2.10M% |
| Revenue Y/Y | 23.07K% |
| P/E ratio | -0.08 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.67 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 3.29 |
| EPS | -$93.72 |
|---|---|
| ROA | -185.47% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.24 |
| Quick ratio | N/A |